Cholangiocarcinoma — Bile Duct Tumors

What Is Cholangiocarcinoma?

Cholangiocarcinoma is a rare but aggressive cancer that arises from the epithelial cells lining the bile ducts. The bile ducts form a network of channels that transport bile from the liver to the gallbladder and small intestine. Although relatively uncommon, cholangiocarcinoma represents the second most common primary hepatic malignancy after hepatocellular carcinoma.

Because cholangiocarcinoma often grows silently and presents at an advanced stage, early detection is challenging. However, advances in endoscopic techniques, imaging, and molecular profiling are improving diagnostic accuracy and expanding treatment options.

Types of Cholangiocarcinoma

Cholangiocarcinoma is classified based on its anatomical location within the biliary tree:

• Intrahepatic cholangiocarcinoma — arises within the liver from the small bile ducts. Accounts for approximately 10-20% of cases. Often presents as a liver mass.
• Perihilar cholangiocarcinoma (Klatskin tumor) — develops at the confluence of the right and left hepatic ducts. This is the most common type, accounting for 50-60% of cases. Named after Gerald Klatskin, who first described this entity.
• Distal cholangiocarcinoma — located in the portion of the bile duct that passes through the pancreas. Accounts for 20-30% of cases and may resemble pancreatic head cancer in presentation.

Risk Factors

• Primary sclerosing cholangitis (PSC) — the strongest known risk factor, with a lifetime risk of 5-15%
• Biliary cysts and Caroli disease — congenital biliary anomalies
• Liver fluke infection — Opisthorchis viverrini and Clonorchis sinensis (prevalent in Southeast Asia)
• Chronic hepatolithiasis — recurrent intrahepatic gallstones
• Hepatitis B and C — chronic viral hepatitis
• Cirrhosis
• Age over 65
• Smoking and obesity
• Toxic exposures — thorotrast (historical contrast agent), dioxins, certain industrial chemicals

Symptoms

Cholangiocarcinoma symptoms depend on the tumor location:

• Jaundice — the most common presenting symptom for perihilar and distal tumors, usually painless and progressive
• Pruritus (itching) — often severe, related to bile salt deposition in the skin
• Dark urine and pale stools
• Abdominal pain — typically a dull ache in the right upper quadrant
• Unexplained weight loss and loss of appetite
• Fatigue and malaise
• Fever — if cholangitis develops due to biliary obstruction

Intrahepatic cholangiocarcinoma may present differently, with abdominal pain or a mass found incidentally on imaging, as it may not cause jaundice until advanced.

Diagnostic Pathway

• Blood tests — elevated bilirubin, alkaline phosphatase, GGT. CA 19-9 is elevated in many cases but is not specific.
• Abdominal ultrasound — initial screening showing bile duct dilation and the level of obstruction
• CT scan with contrast — assesses tumor extent, vascular involvement, and distant metastases
• MRI/MRCP — provides detailed biliary mapping essential for surgical planning, particularly for perihilar tumors
• Endoscopic Ultrasound (EUS) — EUS with FNA/FNB can obtain tissue samples from distal tumors and regional lymph nodes
• ERCP — ERCP allows direct cholangiography, biliary brush cytology, and intraductal biopsy (SpyGlass cholangioscopy) for tissue diagnosis

The Role of ERCP and EUS

Endoscopic procedures are central to the diagnosis and management of cholangiocarcinoma:

• Biliary brush cytology — during ERCP, a brush is passed through the bile duct to collect cells for pathological examination
• Cholangioscopy (SpyGlass) — direct visualization of the bile duct interior allows targeted biopsies and visual assessment of suspicious lesions
• Biliary stenting — placement of plastic or self-expanding metal stents via ERCP to relieve jaundice. For perihilar tumors, bilateral stenting may be necessary.
• EUS-guided tissue acquisition — EUS with FNA provides histological confirmation and can sample suspicious lymph nodes for staging

Treatment Approach

Surgery

Complete surgical resection with negative margins offers the best chance for long-term survival. The type of surgery depends on tumor location: liver resection for intrahepatic tumors, bile duct resection with hepatectomy for perihilar tumors, or pancreaticoduodenectomy (Whipple procedure) for distal tumors.

Liver Transplantation

Selected patients with early-stage perihilar cholangiocarcinoma may be candidates for liver transplantation following neoadjuvant chemoradiation, with excellent long-term outcomes in experienced centers.

Chemotherapy

Gemcitabine plus cisplatin is the standard first-line regimen for advanced disease. Molecular profiling may identify targeted therapy options (IDH1 inhibitors, FGFR inhibitors) for specific tumor subtypes.

Palliative Care

For patients with unresectable disease, biliary stenting via ERCP provides effective palliation of jaundice and pruritus. Photodynamic therapy and radiofrequency ablation via the biliary tract are additional endoscopic options in selected cases.

Prognosis

Prognosis varies significantly by stage at diagnosis. Patients who undergo complete surgical resection have the most favorable outcomes, with five-year survival rates of 20-40%. For unresectable disease, median survival ranges from 6 to 12 months with chemotherapy, though newer targeted therapies and immunotherapy are improving outcomes for selected patients.

Support for Patients

Living with cholangiocarcinoma can be physically and emotionally challenging. Comprehensive supportive care should include nutritional counseling (bile salt supplementation, fat-soluble vitamins), management of pruritus, psychological support, and palliative care integration from the time of diagnosis. Patients are encouraged to seek care at specialized hepatobiliary centers and inquire about clinical trials that may offer access to novel therapies.